Up-regulation of the D1 Dopamine Receptor–Interacting Protein, Calcyon, in Patients With Schizophrenia
Open Access
- 1 March 2003
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 60 (3) , 311-319
- https://doi.org/10.1001/archpsyc.60.3.311
Abstract
THE DOPAMINE hypothesis continues to guide biological research in schizophrenia despite difficulties in identifying a clear disease-associated abnormality in the presynaptic or postsynaptic components of the brain's dopamine system.1- 4 This hypothesis is founded in large part on the therapeutic efficacy of antipsychotic medications, universally attributed to their action at D2 dopamine receptors.2,5- 7 It has been argued that antipsychotic drug treatment may also affect D1 dopamine receptors.2,6,8- 12 Furthermore, D1 receptor involvement in schizophrenia is suggested by the ability of D1 receptor–acting drugs to alter working memory performance,6,10,13- 19 an abnormality that is now widely recognized to be a core feature of schizophrenia.6,13,14,20,21 Both suppression and overstimulation of D1 receptor activity have been shown to result in working memory deficits.15Keywords
This publication has 3 references indexed in Scilit:
- Faculty Opinions recommendation of Prefrontal dopamine D1 receptors and working memory in schizophrenia.Published by H1 Connect ,2002
- Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and retrieval of one-trial avoidance in ratsPsychopharmacology, 2000
- Monoaminergic synapses and schizophrenia: 45 years of neurolepticsJournal of Psychopharmacology, 1998